OBJECTIVES

To assess and compare direct and indirect costs of first line treatment between adult Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL) patients and matched-controls from the general population to identify additional cost drivers.

METHODS

We performed a retrospective cohort study using population based data from the “Echantillon Généraliste des Bénéficiaires” (EGB), a national representative sample of the French population covered by the health insurance system. Cost analysis was performed from the French health insurance perspective and took into account direct and indirect costs (€, 2015). Healthcare costs were studied over the first line treatment period. Costs were evaluated according to different cost components and main lymphoma subgroups. Generalized mixed model were used to assess and adjust cost differences according to lymphoma subgroups

RESULTS

Analyses were performed on 433 lymphoma patients and 1732 controls. The additional cost due to respectively HL and NHL was €32,832 and €36,795. Additional cost amounted to €33,007 for T-Cell NHL and to €36,894 for B-Cell NHL with €43,197 due to Follicular Lymphoma (FL) and €45,300 due to Diffuse Large B Cell Lymphoma (DLBCL). The main additional cost driver was principally inpatient stay mainly regrouping diagnosis related group tariff and cancer related drugs (i.e. rituximab), followed by outpatient medication and productivity loss (i.e. daily allowance). When adjusted, FL and DLBCL were the most costly lymphoma subgroups.

CONCLUSIONS

In a context where decision maker are increasingly interested for real word evidence, this study provides an accurate assessment of lymphoma related cost with high magnitude of details.